Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cells in vitro

Yamaguchi,Masayoshi; Levy,Robert   M.

doi:10.3892/etm.2017.4695

Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cells in vitro

Authors:
- Masayoshi Yamaguchi
- Robert M. Levy
View Affiliations

Affiliations: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA, Department of Clinical Development, Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253, USA
Published online on: June 27, 2017 https://doi.org/10.3892/etm.2017.4695
Pages: 1769-1774

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone is a dynamic tissue that undergoes constant remodeling, with removal by osteoclastic bone resorption and replacement via osteoblastic bone formation and mineralization. Deterioration of bone mass with aging leads to osteoporosis. Bisphosphonates are potent inhibitors of osteoclastic bone resorption. Genistein, an isoflavone, exerts a bone anabolic effect by suppressing osteoclastic bone resorption and stimulating osteoblastic bone formation. The present study was undertaken to investigate the anabolic effects of a combination of alendronate and genistein on osteoclastic differentiation. Preosteoclastic RAW267.4 cells were cultured with alendronate (0.1‑100 µM) and/or genistein (0.1‑100 µM) in vitro. Alendronate or genistein alone had no significant effect on the proliferation and death of RAW267.4 cells. Notably, the combination of the two agents was found to potently and synergistically repress the proliferation and death of RAW267.4 cells. Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor‑κB ligand (RANKL) in vitro. However, combinations of the two agents (0.1‑100 µM) synergistically suppressed the RANKL‑induced osteoclastic differentiation. In conclusion, bisphosphonate and genistein combination therapy may provide a novel strategy for the prevention and treatment of osteoclastic bone resorption.

View Figures

View References

1	Raggatt LJ and Partridge NC: Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
2	Zaidi M, Blair HC, Moonga BS, Abe E and Huang CL: Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res. 18:599–609. 2003. View Article : Google Scholar : PubMed/NCBI
3	Chambers TJ and Fuller K: How are osteoclasts induced to resorb bone? Ann N Y Acad Sci. 1240:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cooper C and Melton LJ III: Epidemiology of osteoporosis. Trends Endocrinol Metab. 3:224–229. 1995. View Article : Google Scholar
5	Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest. 116:1186–1194. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fleisch H: Bisphosphonates: Mechanism of action. Endocr Rev. 19:80–100. 1998. View Article : Google Scholar : PubMed/NCBI
7	Mottaghi P: Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci. 15:175–184. 2010.PubMed/NCBI
8	Caro JJ, Ishak KJ, Huybrechts KF, Raggio G and Naujoks C: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 15:1003–1008. 2004. View Article : Google Scholar : PubMed/NCBI
9	Feng Z, Zeng S, Wang Y, Zheng Z and Chen Z: Bishosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: A systematic review and meta-analysis. PLoS One. 8:e808902013. View Article : Google Scholar : PubMed/NCBI
10	Newcomb PA, Trentham-Dietz A and Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 102:799–802. 2010. View Article : Google Scholar : PubMed/NCBI
11	Oh YH, Yoon C and Park SM: Bisphosphonate use and gastrointestinal tract cancer risk: Meta-analysis of observational studies. World J Gastroentero. 18:5779–5788. 2012. View Article : Google Scholar
12	Faiman B, Pillai AL and Benghiac AG: Bisphosphonate-related osteonecrosis of the Jaw: Historical, ethical, and legal issues associated with prescribing. J Adv Pract Oncol. 4:25–35. 2013.PubMed/NCBI
13	Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM and Murray LJ: Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. 131:E717–E725. 2012. View Article : Google Scholar : PubMed/NCBI
14	Yamaguchi M and Gao-Balch YH: Role of dietary soybean genistein in osteoporosis prevention. Int J Food Sci Nutr Diet. 2:27–34. 2013. View Article : Google Scholar
15	Yamaguchi M: Nutritional factors and bone homeostasis: Synergistic effect with zinc and genistein in osteogenesis. Mol Cell Biochem. 366:201–221. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yamaguchi M and Gao YH: Inhibitory effect of genistein on bone resorption in tissue culture. Biochem Pharmacol. 55:71–76. 1998. View Article : Google Scholar : PubMed/NCBI
17	Gao YH and Yamaguchi M: Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol. 58:767–772. 1999. View Article : Google Scholar : PubMed/NCBI
18	Gao YH and Yamaguchi M: Anabolic effect of daizein on cortical bone in tissue culture: Comparison with genistein effect. Mol Cell Biochem. 194:93–98. 1999. View Article : Google Scholar : PubMed/NCBI
19	Yamaguchi M and Sugimoto E: Stimulatory effect of genistein and daizein on protein synthesis in osteoblastic MC3T3-E1 cells: Activation of aminoacyl-tRNA synthetase. Mol Cell Biochem. 214:97–102. 2000. View Article : Google Scholar : PubMed/NCBI
20	Yamaguchi M and Weitzmann MN: The estrogen 17beta-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-kappaB activity. Int J Mol Med. 23:297–301. 2009.PubMed/NCBI
21	Yamaguchi M and Weitzmann MN: The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol Cell Biochem. 359:399–407. 2012. View Article : Google Scholar : PubMed/NCBI
22	Yamaguchi M and Weitzmann MN: Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int J Mol Med. 27:3–14. 2011.PubMed/NCBI
23	Yamaguchi M and Daimon Y: Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: Involvement of intracellular signaling factors and cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005. View Article : Google Scholar : PubMed/NCBI
24	Izumi T and Yamaguchi M: Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-alpha or thapsigargin. J Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
25	García Palacios V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE and Blair HC: Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens. J Biol Chem. 280:13720–13727. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lee SH, Kim JK and Jang HD: Genistein inhibits osteoclastic differentiation of RAW267.4 cells via regulation of ROS production and scavenging. Int J Mol Sci. 15:10605–10621. 2014. View Article : Google Scholar : PubMed/NCBI
27	Gao YH and Yamaguchi M: Suppressive effect of genistein on rat bone osteoclasts: Involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med. 5:261–267. 2000.PubMed/NCBI
28	Sutherland KA, Rogers HL, Tosh D and Rogers MJ: RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther. 11:R582009. View Article : Google Scholar : PubMed/NCBI